GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Inventory-to-Revenue

Repligen (Repligen) Inventory-to-Revenue : 1.33 (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Repligen Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Repligen's Average Total Inventories for the quarter that ended in Dec. 2023 was $206.8 Mil. Repligen's Revenue for the three months ended in Dec. 2023 was $155.7 Mil. Repligen's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 1.33.

Repligen's Inventory-to-Revenue for the quarter that ended in Dec. 2023 declined from Sep. 2023 (1.60) to Sep. 2023 (1.33)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Repligen's Days Inventory for the three months ended in Dec. 2023 was 214.15.

Inventory Turnover measures how fast the company turns over its inventory within a year. Repligen's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.43.


Repligen Inventory-to-Revenue Historical Data

The historical data trend for Repligen's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Inventory-to-Revenue Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.21 0.21 0.26 0.35

Repligen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 1.32 1.53 1.60 1.33

Competitive Comparison of Repligen's Inventory-to-Revenue

For the Medical Instruments & Supplies subindustry, Repligen's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's Inventory-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Repligen's Inventory-to-Revenue falls into.



Repligen Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Repligen's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (238.277 + 202.321) / 2 ) / 638.764
=220.299 / 638.764
=0.34

Repligen's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (Q: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count ) / Revenue (Q: Dec. 2023 )
=( (211.372 + 202.321) / 2 ) / 155.743
=206.8465 / 155.743
=1.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Repligen  (NAS:RGEN) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Repligen's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=206.8465/88.136*365 / 4
=214.15

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Repligen's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=88.136 / 206.8465
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Repligen Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Repligen's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (Repligen) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453